Hesperadin
Hesperadin is an aurora kinase inhibitor.
Names | |
---|---|
Preferred IUPAC name
N-[(3Z)-2-Oxo-3-(phenyl{4-[(piperidin-1-yl)methyl]anilino}methylidene)-2,3-dihydro-1H-indol-5-yl]ethanesulfonamide | |
Identifiers | |
3D model (JSmol) |
|
ChemSpider | |
PubChem CID |
|
UNII | |
CompTox Dashboard (EPA) |
|
| |
SMILES
| |
Properties | |
C29H32N4O3S | |
Molar mass | 516.66 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references |
The small molecule inhibits chromosome alignment and segregation by limiting the function of mitotic kinases Aurora B and Aurora A. Hesperadin causes cells to enter anaphase much faster, sometimes before the chromosomes are properly bi-oriented.
Hesperadin, like other miotic inhibitors, limits and sometimes can stop the process of mitosis in cells. For this reason, some have considered hesperadin's potential as a cancer-preventing drug.
Hesperadin works as an inhibitor, attaching to the active sites of Aurora A and Aurora B kinases.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.